Reaction Biology

Reaction Biology is a well-established, privately-held CRO providing fee-for-service and integrated drug discovery solutions. Its core strength lies in a broad, integrated assay platform encompassing biochemical profiling, cellular models, biophysical analysis, safety/toxicology, and in vivo pharmacology, with notable specialization in immuno-oncology and kinase research. With over 20 years of operation, a global client base, and a track record of contributing to FDA-approved therapies, the company is positioned as a key enabler in the preclinical R&D outsourcing market. Its business model is purely service-based, generating revenue through contracted research without developing its own therapeutic assets.

Integrated preclinical drug discovery platform offering biochemical assays (extensive kinase/target library), cell-based assays (1000+ cell lines), biophysical assays (SPR, ITC), in vivo pharmacology, safety/toxicology, GMP bioassays, and specialized immuno-oncology services.

Reaction Biology competes in the fragmented preclinical CRO market against large, full-service players like Charles River Laboratories and LabCorp's Covance, as well as numerous niche specialty CROs. Its differentiation is based on deep scientific expertise in areas like kinase profiling, an integrated service portfolio, and a strong reputation for quality and client partnership.